S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
US Dollar Replaced By "Biden Bucks"? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
US Dollar Replaced By "Biden Bucks"? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
US Dollar Replaced By "Biden Bucks"? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
US Dollar Replaced By "Biden Bucks"? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:HZNP

Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

$67.47
+0.37 (+0.55%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$66.69
$68.20
50-Day Range
$66.96
$91.66
52-Week Range
$60.76
$120.54
Volume
2.96 million shs
Average Volume
3.33 million shs
Market Capitalization
$15.54 billion
P/E Ratio
20.82
Dividend Yield
N/A
Price Target
$117.22

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
73.7% Upside
$117.22 Price Target
Short Interest
Healthy
3.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.26mentions of Horizon Therapeutics Public in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$7.35 M Sold Last Quarter
Proj. Earnings Growth
26.70%
From $4.27 to $5.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.19 out of 5 stars

Medical Sector

16th out of 1,117 stocks

Pharmaceutical Preparations Industry

2nd out of 550 stocks

HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Analyst Upgrades and Downgrades

HZNP has been the subject of several research reports. BMO Capital Markets decreased their price objective on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating for the company in a research note on Thursday, August 4th. UBS Group lowered shares of Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and decreased their target price for the company from $137.00 to $71.00 in a research report on Thursday, August 4th. Oppenheimer restated a "buy" rating and set a $140.00 price objective on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. StockNews.com lowered shares of Horizon Therapeutics Public from a "buy" rating to a "hold" rating in a research report on Friday, August 5th. Finally, Morgan Stanley lowered their price target on Horizon Therapeutics Public from $135.00 to $90.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $117.22.

Horizon Therapeutics Public Price Performance

Horizon Therapeutics Public stock traded up $0.37 during midday trading on Friday, hitting $67.47. 2,963,284 shares of the company's stock were exchanged, compared to its average volume of 3,328,654. Horizon Therapeutics Public has a 52-week low of $60.76 and a 52-week high of $120.54. The stock has a 50-day moving average price of $80.67 and a two-hundred day moving average price of $92.69. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05. The company has a market cap of $15.54 billion, a P/E ratio of 20.82, a PEG ratio of 1.67 and a beta of 1.12.

Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.36 by ($0.29). The business had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 EPS. On average, equities research analysts forecast that Horizon Therapeutics Public will post 4.27 earnings per share for the current year.

Insider Buying and Selling

In other Horizon Therapeutics Public news, EVP Sean M. Clayton acquired 745 shares of the business's stock in a transaction on Thursday, August 4th. The shares were bought at an average price of $66.67 per share, with a total value of $49,669.15. Following the transaction, the executive vice president now directly owns 745 shares of the company's stock, valued at approximately $49,669.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Horizon Therapeutics Public news, EVP Sean M. Clayton purchased 745 shares of the firm's stock in a transaction on Thursday, August 4th. The stock was bought at an average cost of $66.67 per share, for a total transaction of $49,669.15. Following the completion of the purchase, the executive vice president now owns 745 shares in the company, valued at approximately $49,669.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $92.48, for a total value of $2,312,000.00. Following the completion of the sale, the chief executive officer now directly owns 435,549 shares in the company, valued at $40,279,571.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,784 shares of company stock valued at $7,350,633. Corporate insiders own 2.50% of the company's stock.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
8/03/2022
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
1,890
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$117.22
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+73.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$534.49 million
Pretax Margin
19.82%

Debt

Sales & Book Value

Annual Sales
$3.23 billion
Cash Flow
$6.48 per share
Book Value
$21.47 per share

Miscellaneous

Free Float
224,624,000
Market Cap
$15.54 billion
Optionable
Optionable
Beta
1.12

Social Links















HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HZNP shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2022?

8 brokerages have issued 12-month target prices for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they anticipate the company's stock price to reach $117.22 in the next year. This suggests a possible upside of 73.7% from the stock's current price.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2022?

Horizon Therapeutics Public's stock was trading at $107.76 at the start of the year. Since then, HZNP stock has decreased by 37.4% and is now trading at $67.47.
View the best growth stocks for 2022 here
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by $0.29. The biopharmaceutical company had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a trailing twelve-month return on equity of 27.90%. The business's revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.62 earnings per share.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.53 billion-$3.60 billion, compared to the consensus revenue estimate of $3.96 billion.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (5.26%), JPMorgan Chase & Co. (2.89%), Allianz Asset Management GmbH (0.98%), Pictet Asset Management SA (0.97%), abrdn plc (0.91%) and Franklin Resources Inc. (0.85%). Insiders that own company stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $67.47.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $15.54 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..
Read More

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.